Surface Oncology Inc logo

SURF

Surface Oncology Inc

$1.73

Earnings Summary

Net Profits
$-25.21Mn

Highlights

Net Profits:

Surface Oncology Inc’s net profit fell -32.83% since last year same period to $-25.21Mn in the Q2 2022. On a quarterly growth basis, Surface Oncology Inc has generated -506.73% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Surface Oncology Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.46
EPS Estimate Current Year
-0.46

Highlights

EPS Estimate Current Quarter:

Surface Oncology Inc’s earning per share (EPS) estimates for the current quarter stand at -0.46 - a -64.29% fall from last quarter’s estimates.

EPS Estimate Current Year:

Surface Oncology Inc’s earning per share (EPS) estimates for the current year stand at -0.46.

Key Ratios

Key ratios of the Surface Oncology Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.46
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.57
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Surface Oncology Inc’s earning per share (EPS) fell -4.55% since last year same period to -0.46 in the Q2 2022. This indicates that the Surface Oncology Inc has generated -4.55% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Surface Oncology Inc’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Surface Oncology Inc’s return on equity (ROE) stands at -0.57.

Dividend Per Share (DPS):

Surface Oncology Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-03
-0.46
-0.46
0%
2022-05-09
-0.28
0.13
146.43%

Company Information

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.

Organisation
Surface Oncology Inc
Headquarters
Cambridge, Massachusetts, US
Employees
51
Industry
Health Technology
CEO
J. Jeffrey Goater